Advertisement

Advertisement

CRVS Stock Latest News

Corvus Stockholders Approve Directors and Governance Proposals

Company AnnouncementsCorvus Stockholders Approve Directors and Governance Proposals

Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained

PremiumRatings

Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained

2M ago

Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results

PremiumCompany Announcements

Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results

2M ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

PremiumThe Fly

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

2M ago

Corvus Pharmaceuticals Announces Board Changes and New Director

PremiumCompany Announcements

Corvus Pharmaceuticals Announces Board Changes and New Director

3M ago

Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls

PremiumThe FlyApple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls

3M ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

The Fly

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

3M ago

Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline

Company Announcements

Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline

4M ago

Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million

PremiumCompany Announcements

Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million

4M ago

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

PremiumThe Fly

Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

4M ago

Corvus Pharmaceuticals files automatic mixed securities shelf

PremiumThe Fly

Corvus Pharmaceuticals files automatic mixed securities shelf

4M ago

PremiumRatings

Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile

4M ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

PremiumThe FlyCorvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

4M ago

Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings

The Fly

Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings

4M ago

Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market

Company Announcements

Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market

4M ago

Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch

PremiumCompany Announcements

Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch

4M ago

Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

PremiumThe Fly

Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

5M ago

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

5M ago

3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts

PremiumMarket News

3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts

6M ago

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

PremiumThe FlyCorvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

6M ago

Mizuho biotech analysts hold an analyst/industry conference call

The Fly

Mizuho biotech analysts hold an analyst/industry conference call

6M ago

Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering

Company Announcements

Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >